VANCOUVER, BC, Feb. 27, 2026 — Equity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus […]

Equity-Insider.com News Commentary VANCOUVER, BC, Feb. 27, 2026 — Industrial silver fabrication accounts for nearly 60% of total global demand, with industrial use reaching 680 million ounces in 2024 as solar photovoltaic installations, electric vehicle production, and AI server manufacturing continue to absorb physical supply[1]. Global EV production is forecast to reach 14 to 15 million units in […]